A Phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer

Urology

Volumn 52, Issue 2, 1998, Pages 257-260

  Smith, David C ^a   Redman, Bruce G ^a   Flaherty, Lawrence E ^a   LI, Lang ^a   Strawderman, Myla ^a   Pienta, Kenneth J ^a  

^a 7303 Cancer and Geriatric Center ^*

Author keywords

[No Author keywords available]

Indexed keywords

DIETHYLSTILBESTROL; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG RESPONSE; GYNECOMASTIA; HUMAN; HYPERSENSITIVITY; MALE; NIPPLE; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; SURVIVAL RATE;

ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; DIETHYLSTILBESTROL; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS;

EID: 0032145396     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00173-3     Document Type: Article

References (21)

1. Eisenberger M.A., Simon R., O'Dwyer P.J., et al. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostate cancer. J Clin Oncol. 3:1985;827-841.
2. Yagoda A., Petrylak D. Cytoxic chemotherapy for advanced hormone refractory prostate cancer. Cancer. 71:(suppl):1993;1098-1109.
3. Eichenberger T., Trachtenberg J. Effects of high-dose Ketoconazole in patients with androgen-independent prostatic cancer. Am J Clin Oncol. 2:(suppl):1988;S104-S107.
4. Witjes F.J., Debruyne F.M., Fernandez del Moral P., et al. Ketoconazole high dose in management of hormonally pretreated patients with progressive metastatic prostate cancer. Urology. 33:1989;411-415.
5. Huggins C., Hodges C.V. Studies on prostatic cancer I. Effect of castration, of estrogen and of androgen injections on serum phosphatases in metastatic carcinoma of the prostate . Cancer Res. 1:1941;293-297.
6. Dreicer R. Metastatic prostate cancer assessment of response to systemic therapy . Semin Urol Oncol. 15:1997;28-33.
7. Kantoff P.W. New agents in the therapy of hormone refractory patients with prostate cancer. Semin Oncol. 22:(1 Suppl 1):1995;32-34.
8. Smith D.C. Secondary hormonal therapy. Semin Urol Oncol. 15:1997;3-13.
9. Byer D.P. The Veterans' Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer. 32:1973;1126-1130.
10. Emtage L.A., George J., Boughton B.J., et al. Haemostatic changes during hormone manipulation in advanced prostate cancer a comparison of DES 3 mg/day and Goserelin 3.6 mg/month . Eur J Cancer. 26:1990;315-319.
11. Blackard C.E. The Veterans' Administration Cooperative Urological Research Group studies of carcinoma of the prostate a review . Cancer Chemother Rep Part. 1 59:1975;225-227.
12. Pavone-Macaluso M., de Voogt H.J., Viggiano G., et al. Comparison of diethylstilbesterol, cyproterone acetate, and medroxyprogesterone acetate in the treatment of advanced prostate cancer final analysis of a randomized phase III trial of the European Organization for Research on the Treatment of Cancer Urological group . J Urol. 136:1986;624-630.
13. Byer D.P., Corle D.K. Hormone therapy for prostate cancer results of the Veterans Administration Cooperative Urological Research Group studies . NCI Monogr. 7:1988;165-170.
14. Scott W.W., Menon M., Walsh P.C. Hormonal therapy of prostatic cancer. Cancer. 45:(7 suppl):1980;1929-1936.
15. McLeod D.G., Murphy G.P., Priore R. Comparison of megace, stilphostril, megace plus DES, or streptozotosin in metastatic prostatic cancer in patients with hormonal failure and prior radiotherapy. Urology. 32:1988;431-436.
16. Cervellino J.C., Araujo C.E., Pirisi C., et al. Combined hormonal therapy with high dose diethystilbesterol diphosphate (DES-DP) intravenous infusion plus vindesine (VND) for the treatment of advanced prostatic carcinoma a controlled study . J Surg Oncol. 43:1990;250-253.
17. Ferro M.A., Gillatt D., Symes M.O., et al. High-dose intravenous estrogen therapy in advanced prostatic carcinoma. Urology. 34:1989;134-138.
18. Citrin D.L., Kies M.S., Wallemark C.-B., et al. A phase II study of high-dose estrogens (diethylstilbesterol diphosphate) in prostate cancer. Cancer. 56:1985;457-460.
19. Colapinto V., Aberhart C. Clinical trial of massive stilboestrol diphosphate therapy in advanced carcinoma of the prostate. Br J Urol. 33:1961;171.
20. Hawtrey C.F., Welch M.J., Schmidt J.D., et al. Paraplegia and paraparesis due to prostatic cancer. Urology. 4:1975;431-434.
21. Trafford H.S. The place of Hovan(R) in the treatment of prostatic cancer. Br J Urol. 37:1965;317.